TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neupath Health Inc. ( (TSE:NPTH) ) has provided an update.
NeuPath Health Inc. reported record second-quarter revenue of $23.6 million, marking a 25% increase year-over-year, alongside a 69% rise in adjusted EBITDA to $2.2 million. The company’s improved financial performance is attributed to increased capacity utilization and strong demand for Arthrosamid, positioning NeuPath for continued growth and strategic expansion in the latter half of 2025.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc. operates a network of clinics specializing in chronic pain treatment. The company focuses on optimizing patient outcomes and enhancing clinic operations, with a market emphasis on innovative procedures such as Arthrosamid.
Average Trading Volume: 84,534
Technical Sentiment Signal: Buy
Current Market Cap: C$13.12M
For detailed information about NPTH stock, go to TipRanks’ Stock Analysis page.